Ultimovacs ASA (Norway) Management Evaluation
| ULTI Stock | NOK 1.98 0.05 2.46% |
Ultimovacs ASA employs about 23 people. The company is managed by 10 executives with a total tenure of roughly 54 years, averaging almost 5.0 years of service per executive, having 2.3 employees per reported executive. Inspection of Ultimovacs ASA's management performance can provide insight into the company performance.
| Antonius Berkien Insider Chief Officer |
| Pr Gaudernack Insider Chief Officer |
Ultimovacs |
Ultimovacs ASA Management Team Effectiveness
The company has return on total asset (ROA) of (0.2021) % which means that it has lost $0.2021 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3318) %, meaning that it generated substantial loss on money invested by shareholders. Ultimovacs ASA's management efficiency ratios could be used to measure how well Ultimovacs ASA manages its routine affairs as well as how well it operates its assets and liabilities.Ultimovacs ASA Workforce Comparison
Ultimovacs ASA is rated first in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 71.0. Ultimovacs ASA totals roughly 23.0 in number of employees claiming about 32% of stocks in Biotechnology industry.
Ultimovacs ASA Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Ultimovacs ASA Price Series Summation is a cross summation of Ultimovacs ASA price series and its benchmark/peer.
Ultimovacs ASA Notable Stakeholders
An Ultimovacs ASA stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ultimovacs ASA often face trade-offs trying to please all of them. Ultimovacs ASA's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ultimovacs ASA's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Antonius Berkien | Chief Officer | Profile | |
| Pr Gaudernack | Chief Officer | Profile | |
| Hans Eid | Chief Officer | Profile | |
| Audun Tornes | Chief Officer | Profile | |
| Gudrun Troite | Head Coordination | Profile | |
| Anne Worsoe | Head Communication | Profile | |
| Oivind Foss | Head Operations | Profile | |
| Carlos Sousa | Chief Officer | Profile | |
| Ingunn Westgaard | Head Research | Profile | |
| Jens MD | Chief Officer | Profile |
About Ultimovacs ASA Management Performance
The success or failure of an entity such as Ultimovacs ASA often depends on how effective the management is. Ultimovacs ASA management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ultimovacs management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ultimovacs management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company was incorporated in 2011 and is headquartered in Oslo, Norway. ULTIMOVACS ASA is traded on Oslo Stock Exchange in Norway.
Ultimovacs ASA Workforce Analysis
Traditionally, organizations such as Ultimovacs ASA use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ultimovacs ASA within its industry.Ultimovacs ASA Manpower Efficiency
Return on Ultimovacs ASA Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 7.2M | |
| Net Loss Per Executive | 16.5M |
Other Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.